Evaluation of high-grade astrocytoma recurrence patterns after radiotherapy in the era of temozolomide: A single institution experience

Abstract

Of the selected patients, 80% had ≥81-95% of the Vol within 100% of the prescribed dose and predominantly had central or in-field recurrences. These results are comparable with those from the literature.

Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)

“…A major challenge in the treatment of glioblastoma is the insufficiency of the standard radiation dose to effectively control the tumor. Supporting this notion is the observation of many publications that 75–93 % of recurrences/progressions manifest within the primary tumor area [6] , [7] , [8] , [9] , [10] . To address this concern, several trials have explored dose escalation concepts, with some studies reporting favorable outcomes in terms of OS and progression-free survival (PFS) [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] .…”